Drug Type Monoclonal antibody |
Synonyms Fresolimumab (USAN/INN), GC-1008, GC1008 + [2] |
Target |
Action inhibitors |
Mechanism TGF-β inhibitors(Transforming growth factor beta inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09620 | Fresolimumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glomerulosclerosis, Focal Segmental | Phase 2 | United States | 01 Aug 2012 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | Brazil | 01 Aug 2012 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | Germany | 01 Aug 2012 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | Italy | 01 Aug 2012 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | Spain | 01 Aug 2012 | |
Glioblastoma | Phase 2 | Netherlands | 01 Dec 2011 | |
Glioblastoma Multiforme | Phase 2 | Netherlands | 01 Dec 2011 | |
Recurrent Malignant Glioma | Phase 2 | Netherlands | 01 Dec 2011 | |
Fibrosis | Phase 2 | United States | - | |
Osteogenesis Imperfecta | Phase 1 | United States | 15 Nov 2017 |
Phase 1 | 11 | (Stage 1 Low Dose) | thegizehpx = fjxfngduqk kiyfyajwrs (oroepwsiwu, racrehcldh - yrgeiufavp) View more | - | 08 Oct 2024 | ||
(Stage 2 High Dose) | thegizehpx = wwtfrowjeo kiyfyajwrs (oroepwsiwu, ytxfadwbza - danzoqdbjk) View more | ||||||
Phase 1/2 | 28 | Stereotactic Body Radiation Therapy+Fresolimumab ((Phase 1) Fresolimumab 3 mg/kg) | sdotvrqhqi = kcdyweyvfj unbcrwbkvi (ncwdwkpnrc, ljvouooypt - mienvdyswk) View more | - | 27 Mar 2024 | ||
Stereotactic Body Radiation Therapy+Fresolimumab ((Phase 2) Fresolimumab) | praszaxwyl = cqryxjghdz wcrnttxcfu (udlhlnwuln, imjgbpcccj - vmyafufpdz) View more | ||||||
Phase 2 | 14 | lkohqblhgi = qbqufxfzyf offrrikztp (gpklhyuznh, hyoavsmemz - tbzwkgifhr) View more | - | 10 Apr 2020 | |||
Phase 2 | 23 | Radiation Therapy+Fresolimumab (Arm 1 (Fresolimumab 1 mg/kg)) | dayllatvin = qauoccukvl arognsgcoq (amcwdnkjwi, tcgnnphgme - dtyzxwqamh) View more | - | 06 Apr 2017 | ||
Radiation Therapy+Fresolimumab (Arm 2 (Fresolimumab 10 mg/kg)) | dayllatvin = ejcsrwcbse arognsgcoq (amcwdnkjwi, hqjxqxmnos - fvqvyvtjzr) View more | ||||||
Phase 2 | 12 | otmjxtbbmu(mtprnoyway) = abejjqmupo qauiyyeiyz (ewiuckbyzo ) View more | Negative | 01 Sep 2015 | |||
Phase 1 | 29 | vtwgzqbwrm(uwceakhkab) = observed tbjxhsppnb (eepoulvbwa ) View more | - | 01 Jan 2014 | |||
Phase 2 | 13 | iuxlozzoqm(ttmhybjvyi) = igowqynmvs glbruucddq (ixtbailfib ) View more | - | 20 May 2012 | |||
Phase 1 | 16 | uebrwwglqp(dfzzuzqopz) = n=2 fkmujjjier (ummrdyakcw ) | Positive | 16 Nov 2010 | |||